SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt receives USFDA approval for generic version of Parkinsons drug Requip XL

28 Aug 2012 Evaluate

Wockhardt has received USFDA approval for marketing generic version of 2mg, 4mg, 6mg, 8mg & 12 mg extended-release tablets containing Ropinirole Hydrochloride, which is used in the treatment of Parkinson's disease. Roinirole extended release tablet is the generic name for the brand Requip XL, marketed in the US by Glaxo SmithKline. The company would be launching the product as soon as possible.

In the US generic pharmaceutical market, Workhardt has been consistently growing maket shares for all its products. In many instance, Workhardt, by virtual of amongst the few players to market technically challenging product has reaped the advantage of being an early entrant

Wockhardt will be manufacturing the extended release tablets of Ropinirole at its facility in at Aurangabad India. The technology for the tables was developed in-house.

According to IMS Health, the total market for this product in the US is about $58 million and the incidence of Parkinson's disease has been increasing worldwide.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1396.80 37.70 (2.77%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×